The results indicate that DAPA significantly counteracted IL-10, IL-13, and IL-18 release in the septic group with normal glycemia compared to the vehicle-treated septic group with normal glycemia (Figure 5N,O,Q), while DAPA significantly decreased eotaxin, fractalkine, IL-1α, IL-2, IL-4, IL-5, IL-6, and MIP-2 levels in the septic group with diabetes (Figure 5H,J–M,T). This evidence concerns the gene CX3CL1 and diabetes mellitus.